Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Craufurd

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Human Brain Mapping|November 22, 2011
Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophyRachael I Scahill, Nicola Z Hobbs, Miranda J Say, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|February 27, 2015
Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studiesJenny Callaghan, Cheryl Stopford, Natalie Arran, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Human Brain Mapping|November 22, 2011
Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophyRachael I Scahill, Nicola Z Hobbs, Miranda J Say, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|February 27, 2015
Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studiesJenny Callaghan, Cheryl Stopford, Natalie Arran, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Pageof 7